

Special Issue

Radiation Dose in Cancer Radiotherapy

Message from the Guest Editor

More than half of cancer patients receive radiotherapy as part of their treatment and ongoing developments in the field have ensured that radiotherapy remains a key treatment option. Technological developments have seen the implementation of image guided, high precision treatments such as stereotactic radiosurgery (SRS) and stereotactic ablative radiotherapy (SABR) employing high dose, low fraction treatment regimens. The number of proton and carbon beam therapy facilities continues to rise globally and developments in molecular radiotherapy and brachytherapy have also been seen. Synergistic approaches using biological and immunotherapy agents are also being developed. These approaches have been supported by developments in preclinical investigations in small animal imaging and irradiation (SARP). All of these developments require accurate determination of the radiation dose to ensure clinical outcomes are not compromised. The aim of this special issue is to provide an up to date overview of developments in all aspects of Radiation Dose in Cancer Radiotherapy.

Guest Editor

Prof. Dr. Andrew Nisbet

Department of Medical Physics & Biomedical Engineering, Faculty of Engineering Science, University College London, London, UK

Deadline for manuscript submissions

closed (31 October 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/145156

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)